In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company’s stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback